跳至主要内容
临床试验/JPRN-UMIN000003365
JPRN-UMIN000003365已完成未知

A prospective study of leukemic transformation control and hematopoietic recovery in patients with myelodysplastic syndrome(MDS) receiving iron chelation therapy with deferasirox(Exjade) - A prospective study of leukemic transformation control and hematopoietic recovery in patients with myelodysplastic syndrome(MDS) receiving iron chelation therapy with deferasirox(Exjade)

Division of Hematology, Department of Medicine, Showa University School of Medicine0 个研究点目标入组 50 人开始时间: 2010年4月1日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 85years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1, heavy renal and liver disorder. 2, during pregnancy, the lactation period. 3, allergy to Deferasirox 4, The case who cannot receive informed consent from patients. 5, The patients who received chemotherapy, except for oral chemoterapy.

研究者

发起方
Division of Hematology, Department of Medicine, Showa University School of Medicine

相似试验